Bangkok Dusit Medical Services Public Company Limited
Bangkok Dusit Medical Services Public Company Limited (BDULF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bdulf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bangkok Dusit Medical Services Public Company Limited (BDULF) measures how much investors pay for each dollar of the company's trailing earnings. BDULF's current PE ratio of 18.59x is calculated by dividing its stock price of $0.56 by its TTM earnings per share of $0.98. −44.1% discount vs 5Y avg 33.2x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%30.9x
MedianQ3 · 75%48.9x
Max
At 18.59x, BDULF's current P/E is lower than in 10% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Care Facilities · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bangkok Dusit Medical Services Public Company LimitedYou BDULF | $8.8B | 18.59x | -67.9% | $0.98 |
 Swedish Orphan Biovitrum AB (publ) BIOVF | $16.4B | 234.66x | +304.8% | $1.38 |
 CSPC Pharmaceutical Group Limited CSPCY | $10.5B | 25.38x | -56.2% | $1.32 |
 Grifols, S.A. GIFLF | $7.6B | 16.98x | -70.7% | $0.58 |
 M3, Inc. MTHRF | $7.3B | 23.92x | -58.7% | $72.99 |
 M3, Inc. MTHRY | $6.7B | 21.01x | -63.8% | $38.45 |
 Recordati Industria Chimica e Farmaceutica S.p.A. RCDTF | $12.2B | 25.91x | -55.3% | $2.15 |
Industry Average 6 peers with valid PE | — | 57.98x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 19.24x | $1.00 | -33.7% | |
2024-12-31 FY2024 | 29.04x | $1.01 | -6.3% | |
2023-12-31 FY2023 | 30.98x | $0.90 | -18.4% | |
2022-12-31 FY2022 | 37.96x | $0.79 | -22.4% | |
2021-12-31 FY2021 | 48.91x | $0.50 | +8.9% | |
2020-12-31 FY2020 | 44.92x | $0.45 | +89.6% | |
2019-12-31 FY2019 | 23.70x | $0.99 | -45.9% | |
2018-12-31 FY2018 | 43.80x | $0.59 | +41.7% | |
2017-12-31 FY2017 | 30.91x | $0.66 | -19.2% | |
2016-12-31 FY2016 | 38.27x | $0.54 | -9.6% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bangkok Dusit Medical Services Public Company Limited (BDULF) measures how much investors pay for each dollar of the company's trailing earnings. BDULF's current PE ratio of 18.59x is calculated by dividing its stock price of $0.56 by its TTM earnings per share of $0.98.
Frequently asked questions
BDULF pe ratio · 6 questionsBDULF's current PE ratio is 18.59x as of 2026-06-08, based on a stock price of $0.56 and TTM EPS of $0.98. Data sourced from Financial Modeling Prep via BDULF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bangkok Dusit Medical Services Public Company Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08